Numab Therapeutics AG is aiming to accelerate the development of its pipeline of multi-targeted antibodies in solid tumors and inflammation, and to market its own products, with the help of CHF100m ($110m) from a just-completed series C financing.
The Promise Of Numab's Multispecific Antibodies
CHF100m Raised In Series C Financing
Swiss biotech Numab Therapeutics has raised an oversubscribed series C financing of CHF100m to accelerate the development of its multispecific antibodies, from investors attracted by the company’s thoughtful approach to developing its technology.
